Actively Recruiting
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Led by Elsan · Updated on 2026-04-23
35
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims at enrolling patients with solid tumors at metastatic stage, considered long responders to immunotherapy (\> 6 months) and displaying disease progression. In this study, the investigator wants to evaluate specific modalities of stereotactic radiotherapy, with 3 sessions, each of 8 Gy, lasting 20 minutes and spaced 72 hours apart (Day 1, Day 4, Day 7). The radiotherapy device itself is not the subject of this study and will be used in accordance with its CE mark and indications. The objective of the study is to assess the ability of stereotactic radiotherapy to restore the lost efficacy of immunotherapy. In particular, the abscopal effect will be assessed, i.e. the action of irradiating a particular target lesion and observing an effect on other distant metastases.
CONDITIONS
Official Title
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years of age or older
- Patient with a metastatic solid tumor
- Patient with at least one target lesion for radiotherapy and other measurable secondary lesions
- Measurable disease according to RECIST 1.1 and iRECIST criteria
- Patient undergoing anti-PD1 immunotherapy as part of standard care
- Disease progression after at least 6 months of immunotherapy
- Performance Status of 0 or 1
- Patient eligible for stereotactic radiotherapy
- Patient affiliated with or benefiting from a social security scheme
- Patient informed about the study and signed informed consent
- Patient willing and able to undergo all study examinations and procedures
You will not qualify if you...
- Patient previously received radiotherapy since starting immunotherapy
- Disease progression not confirmed at inclusion stage
- Presence of active implantable or wearable medical devices that could interfere with radiotherapy
- Patient with hematological cancer
- Symptomatic patient needing rapid change of systemic treatment
- Concurrent participation in another clinical trial or recent use of investigational product within 30 days
- Pregnant or breastfeeding women
- Patient under legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Clinical
Soyaux, Charente, France, 16800
Actively Recruiting
Research Team
V
Vincent ATALLAH, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here